CETO3®: the new Omega
CETO3® is a natural fish oil ingredient which contains a high level of Cetoleic acid (Omega-11) with Omega-3 (EPA and DHA). CETO3® is derived from North Atlantic herring. High levels of Omega-11 is uniquely found in North Atlantic pelagic fish. Omega-11 have proven to increase the human body’s own production of EPA/DHA.
CET03® points of difference
- Contains Cetoleic acid (Omega-11) and Omega-3 EPA/DHA
- Cetoleic acid is the main fatty acid in North Atlantic herring
- Cetoleic acid stimulates and increases the body’s own production of EPA/DHA
- Single source fish Omega-3 ingredient
- No fishy smell, taste or unpleasant reflux – can be taken as both liquid and capsule\
- Immediate processing: from fresh fish to oil takes as little as 30 minutes
- Human grade production process without any solvent or chemicals
- Low on pollutants as pelagic fish swim neither up in the surface or bottom of the ocean
- CETO3® is harvested and produced in Norway
- Low carbon footprint
Equal effectiveness of omega-3 polyunsaturated fatty acids (n-3 PUFAs) from CET03 and fish oil in elevating the omega-3 index
The nature of the source of omega-3 PUFAs can affect bioavailability of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). A new source of omega-3 is CET03® (Omega-11 and Omega-3), unlike Fish oil (FOil), contains high levels of monounsaturated fatty acid Cetoleic acid (Omega-11).
This study aimed to examine the effect of CET03® in healthy subjects on the omega-3 PUFA status over 12 weeks and to compare it with the same length of intervention with fish oil (FOil). The Omega-3 Index, a measurement of the DHA and EPA content of red blood cells compared to the total percentage content of all other identifiable fatty acids, was used to quantify the omega-3 status.
In this randomised double-blind study, 30 participants were randomly allocated to either the:
- CET03® group: DHA+EPA dose: 400 mg/day per 2 capsules, n=14
- FOil group: DHA+EPA dose: 600 mg/day/2 capsules, n=16
Following completion of the 12 week intervention, the increase in Omega-3 Index was comparable between both groups
- CET03®: 5.73 ± 1.38%; p<0.00001
- FOil: 6.24 ± 1.35%; p<0.0003
The results of this study demonstrate that the effect of CET03® on the Omega-3 Index increase over 12 weeks is comparable to FOil. Given that CET03® typically contains 200 mg of EPA/DHA per 1000 mg capsule compared to 300 mg EPA/DHA in the fish oil capsules used in this trial, it would appear from the results of this pilot study, on a pro-rata dose equivalence, that CET03® might deliver a 50% improvement in the Omega-3 Index.
Reference: Wakeman M. Equal effectiveness of omega-3 polyunsaturated fatty acids (n-3 PUFAs) from CET03 and fish oil in elevating the omega-3 index: A 12-week randomized placebo controlled parallel study. International Journal of Scientific Research. 2024;13(1)
For more information, contact Craig Fallshaw at craig@cmgrouponline.com.au